表阿霉素为主的联合方案治疗非霍奇金淋巴瘤

The clinical treatment of CEOD-B regimen for NHL

目的 评价不需有干细胞移植支持的表阿霉素为主的联合治疗非霍奇金淋巴瘤 (NHL)的方案 (CEOD -B) ,以探索一种高效、低毒的治疗方案。方法 实验组采用CEOD -B方案 ,对照组采用COHD -B方案。治疗 4个疗程后进行近期疗效评价。结果 实验组与对照组治疗的有效率分别为 91.83%及 6 1.2 3% ,两组差异有极显著性 (P <0 .0 0 1)。用药后两组血常规变化差异无显著性 (P >0 .0 5 ) ,毒副反应中除心脏毒性差异外 ,其余差异均无显著性。结论 CEOD -B为一高效。

OBJECTIVE To evaluate the CEOD-B regimen without the support of Hematopoietic stem cell transplantation in NHL and to find an effective and low toxicity regimen.METHODS The experimental group adopted CEOD-B regimen and the control group adopted COHD-B regimen.Four treatment courses were observed and the therapatic effects were evaluate.RESULTS The effective rate of the experimental group is 91.83% and that of the control group is 61.23%. There is significant difference between the two groups ( P <0.01). No significant is difference blood RT index between the two groups ( P >0.05).Regard as side effect, there is no significant difference( P >0.05) except heart toxicity( P =0.05).CONCLUSION CEOD-B is an effective and low toxicity regimen in the therapy of NHL.